KRAS-targeted therapies in cancer: novel approaches and overcoming resistance.

83 Moreover, STK11 mutations and high CD274 expression trended towards resistance but did not reach statistical significance. 83 Recent clinical data further confirmed that KEAP1–NFE2L2 pathway activation and low transcription termination factor 1 expression are major determinants of poor sotorasib efficacy, while the KL (KRAS–LKB1/STK11) transcriptional subtype—characterised by STK11 loss, KEAP1 comutation and a non-inf

also in 111,027 other papers